Silver Book Fact

Use of an epidermal growth factor inhibitor in the treatment of metastatic colon cancer patients without the KRAS gene mutation saw survival rates of 15.6 months, compared to 5.6 months in those without the mutation.

Lievre, A, J Bachet, V Boige, A Cayre, D LeCorre, E Buc, et al. KRAS Mutations as an Independent Prognostic Factor in Patients with Advanced Colorectal Cancer Treated with Cetuximab. J Clin Oncol. 2008; 26(3): 374-9. http://www.ncbi.nlm.nih.gov/pubmed/18202412

Reference

Title
KRAS Mutations as an Independent Prognostic Factor in Patients with Advanced Colorectal Cancer Treated with Cetuximab
Publication
J Clin Oncol
Publication Date
2008
Authors
Lievre, A, J Bachet, V Boige, A Cayre, D LeCorre, E Buc, et al
Volume & Issue
Volume 26, Issue 3
Pages
374-9
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • The standard treatment for prostate cancer used to require radical prostatectomy. Now, less invasive therapies like brachytherapy have been shown to have equal outcomes with fewer side effects.  
  • Every additional dollar spent on newer, less toxic hormonal therapy for breast cancer patients has produced health gains valued at between $27.03 and $36.81.  
  • Following the current path, breast cancer incidence rate will increase by 50.8% between 2003 and 2023. If an alternative path is taken, cases will increase by 32.2% between 2003 and…  
  • For women age 40 or older, timely mammograms could reduce breast cancer mortality by about 16%–compared to those who are not screened.  
  • The overall five-year survival rate for men with prostate cancer is 99 percent—up from 43 percent in 1975.